- RecruitingPHASE3
REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
This study is testing a new medicine, ION582, for Angelman syndrome. It wants to see if the medicine is safe and helps children and adults with the condition, which affects development and causes seizures.
For: Angelman SyndromeUnited States · Australia · Canada - RecruitingPHASE1, PHASE2
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
This study, called HALOS, is looking at a new medicine called ION582 for Angelman syndrome. It aims to see if different doses are safe, how the body handles the medicine, and how it affects the condition. It includes children and adults up to 50 years old.
For: Angelman SyndromeUnited States · Australia · France